GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Cyclically Adjusted PS Ratio

Cerus (CERS) Cyclically Adjusted PS Ratio : 2.59 (As of Apr. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Cerus's current share price is $1.71. Cerus's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.66. Cerus's Cyclically Adjusted PS Ratio for today is 2.59.

The historical rank and industry rank for Cerus's Cyclically Adjusted PS Ratio or its related term are showing as below:

CERS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.95   Med: 8.35   Max: 14.94
Current: 2.6

During the past years, Cerus's highest Cyclically Adjusted PS Ratio was 14.94. The lowest was 1.95. And the median was 8.35.

CERS's Cyclically Adjusted PS Ratio is ranked worse than
53.98% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs CERS: 2.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cerus's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.258. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.66 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cerus Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cerus's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Cyclically Adjusted PS Ratio Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.74 12.71 11.69 5.82 3.28

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.82 4.68 3.82 2.49 3.28

Competitive Comparison of Cerus's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Cerus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's Cyclically Adjusted PS Ratio falls into.



Cerus Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cerus's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.71/0.66
=2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cerus's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Cerus's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.258/129.4194*129.4194
=0.258

Current CPI (Dec. 2023) = 129.4194.

Cerus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.105 99.695 0.136
201406 0.115 100.560 0.148
201409 0.136 100.428 0.175
201412 0.120 99.070 0.157
201503 0.081 99.621 0.105
201506 0.092 100.684 0.118
201509 0.082 100.392 0.106
201512 0.098 99.792 0.127
201603 0.077 100.470 0.099
201606 0.091 101.688 0.116
201609 0.099 101.861 0.126
201612 0.098 101.863 0.125
201703 0.068 102.862 0.086
201706 0.091 103.349 0.114
201709 0.098 104.136 0.122
201712 0.142 104.011 0.177
201803 0.109 105.290 0.134
201806 0.117 106.317 0.142
201809 0.115 106.507 0.140
201812 0.121 105.998 0.148
201903 0.128 107.251 0.154
201906 0.132 108.070 0.158
201909 0.128 108.329 0.153
201912 0.146 108.420 0.174
202003 0.118 108.902 0.140
202006 0.131 108.767 0.156
202009 0.142 109.815 0.167
202012 0.168 109.897 0.198
202103 0.138 111.754 0.160
202106 0.184 114.631 0.208
202109 0.210 115.734 0.235
202112 0.230 117.630 0.253
202203 0.215 121.301 0.229
202206 0.232 125.017 0.240
202209 0.223 125.227 0.230
202212 0.248 125.222 0.256
202303 0.174 127.348 0.177
202306 0.215 128.729 0.216
202309 0.220 129.860 0.219
202312 0.258 129.419 0.258

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cerus  (NAS:CERS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cerus Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cerus's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451

Cerus (CERS) Headlines

From GuruFocus

Cerus Corporation to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 02-10-2023